All Posts | Links Medicus - Free Medical News & Perspective

NEW Personal View—Non-invasive respiratory support in the management of acute #COVID19 #pneumonia: considerations for clinical practice and priorities for research

From Prof Hugh Montgomery & colleagues https://t.co/LLEFz2VLFu pic.twitter.com/owgAjLX5Z6

— The Lancet Respiratory Medicine (@LancetRespirMed) November 10, 2021

M-A: Convalescent plasma does not reduce mortality in COVID-19.

21 Nov, 2021 | 23:09h | UTC

Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials – BMC Infectious Diseases

RCT: Another study shows convalescent plasma does not improve outcomes in critically ill patients with Covid-19.

RCT: Convalescent plasma does not improve outcomes and may be harmful to hospitalized patients with COVID-19.

NIH study shows no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms.

M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.

RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.

Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark – “The IFR was low for people younger than 51 years without comorbidity during the two waves (combined IFR = 3.36 per 100,000 infections)”.

21 Nov, 2021 | 23:12h | UTC

Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark – The Journal of Infectious Diseases

Commentary on Twitter

New in JID: A study in Denmark found that the SARS-CoV-2 infection fatality rate was low for people younger than 51 and otherwise healthy, increased with age and comorbidities, and declined from the 1st to the 2nd wave of the pandemic.

📄 https://t.co/lenryomRJ3 #IDSAJournals pic.twitter.com/TT8RefGjHw

— IDSA (@IDSAInfo) November 20, 2021

Is Delta the last Covid ‘super variant’?

21 Nov, 2021 | 23:07h | UTC

Is Delta the last Covid ‘super variant’? – The Guardian

RCT: Among patients with bipolar disorder or depression who had survived a recent suicide-related event, Lithium as an add on therapy was not effective for the prevention of repeat suicide-related outcomes.

21 Nov, 2021 | 22:59h | UTC

Lithium Treatment in the Prevention of Repeat Suicide-Related Outcomes in Veterans With Major Depression or Bipolar Disorder – JAMA Psychiatry (free for a limited period)

Author Interview: Lithium for Suicide-Related Outcome Prevention in Veterans With Major Depression or Bipolar Disorder

Commentary: Lithium Added To Current Tx Fails to Reduce Suicide-Related Events in Veterans – Physician’s Weekly

Commentary on Twitter

VA Trial findings suggest simply adding lithium to existing medication in patients with #bipolar disorder or major depressive disorder is unlikely to be effective for preventing a broad range of repeat suicide-related events. https://t.co/QOj5UhEFKh

— JAMA Psychiatry (@JAMAPsych) November 17, 2021

No, vaccinated people are not ‘just as infectious’ as unvaccinated people if they get COVID.

21 Nov, 2021 | 23:05h | UTC

No, vaccinated people are not ‘just as infectious’ as unvaccinated people if they get COVID – The Conversation

M-A: In patients with Non-ST Elevation Acute Coronary Syndromes, pretreatment with oral P2Y12 inhibitors prior to angiography was associated with increased risk of bleeding and no difference in cardiovascular outcomes.

21 Nov, 2021 | 22:58h | UTC

Assessment of Pretreatment With Oral P2Y12 Inhibitors and Cardiovascular and Bleeding Outcomes in Patients With Non-ST Elevation Acute Coronary Syndromes: A Systematic Review and Meta-analysis – JAMA Network Open

Invited Commentary: Pretreatment in the Setting of Non–ST-Elevated Acute Coronary Syndrome—When It Is Time to Change – JAMA Network Open

Consensus Statement: U.S. Multi-Society Task Force on Colorectal Cancer now suggests average-risk CRC screening begins at age 45.

21 Nov, 2021 | 23:01h | UTC

Updates on Age to Start and Stop Colorectal Cancer Screening: Recommendations From the U.S. Multi-Society Task Force on Colorectal Cancer – Gastroenterology

News release: US Multi-Society Task Force on colorectal cancer releases updated screening recommendations - American Gastroenterological Association

State of the Art Review: Screening and prevention of colorectal cancer.

USPSTF Statement: Start colorectal cancer screening at 45 years for most patients.

ACG Clinical Guidelines: Start colorectal cancer screening at 45

Overdiagnosis: it’s official – the term is now included in the medical subject headings (MeSH) vocabulary.

21 Nov, 2021 | 22:53h | UTC

Overdiagnosis: it’s official – The BMJ

Overdiagnosis: what it is and what it isn’t – BMJ Evidence Based Medicine

Overdiagnosis across medical disciplines: a scoping review – The BMJ Open

Too much medical care: bad for you, bad for health care systems – STAT News

Screening: How overdiagnosis and other harms can undermine the benefits – Health News Review

Overdiagnosis: causes and consequences in primary health care – Canadian Family Physician

Five warning signs of overdiagnosis – The Conversation

What is overdiagnosed cancer? And why does it matter? – Croakey

Blame rising cancer overdiagnosis on ‘irrational exuberance’ for early detection – STAT

Preventing overdiagnosis and the harms of too much sport and exercise medicine – British Journal of Sports Medicine

Study shows that current definitions of chronic kidney disease overestimate the CKD burden in older individuals and results in overdiagnosis.

Opinion | More kids are being diagnosed with ADHD for borderline (yet challenging) behaviors. Our new research shows why that’s a worry

A food allergy epidemic… or just another case of overdiagnosis?

An epidemic of overdiagnosis: Melanoma diagnoses sky rocket

[Not published yet] Single-dose HPV vaccine highly effective, researchers say – “Results of randomized controlled trial in Kenya bring new energy to eliminate cervical cancer worldwide”.

21 Nov, 2021 | 22:56h | UTC

Single-dose HPV vaccine highly effective, researchers say – University of Washington School of Medicine

A national HPV vaccination program in England was associated with an estimated reduction in cervical cancer rates of 87% for those offered the vaccine at age 12–13 years.

Three-year follow-up of 2-dose versus 3-dose HPV vaccine

Nationwide cohort study in Sweden shows HPV vaccination linked to reduced risk of invasive cervical cancer

CDC: 92% of Human Papillomavirus–Attributable Cancers can be Targeted by HPV Vaccination

Meta-Analysis: Population-level Impact of HPV Vaccination Programs

Infographic | Decarbonizing healthcare in low and middle income countries: potential pathways to net zero emissions.

21 Nov, 2021 | 22:52h | UTC

Decarbonising healthcare in low and middle income countries: potential pathways to net zero emissions – The BMJ

Commentary on Twitter

NEW #BMJInfographic highlights some strategies for sustainable healthcare during the climate emergency @will_s_t https://t.co/ZsQeI9dxEW pic.twitter.com/jXTn65EHDW

— The BMJ (@bmj_latest) November 11, 2021

Optimizing the use of Twitter for research dissemination: The “Three Facts and a Story” randomized-controlled trial.

21 Nov, 2021 | 22:48h | UTC

Optimizing the use of twitter for research dissemination: The “Three Facts and a Story” randomized-controlled trial – Journal of Hepatology

Perspective: How Twitter is Changing Medical Research

Keeping Up With Cardiology: Old-School Learning Versus the Twittersphere – TCTMD

Scientists on Twitter: Preaching to the choir or singing from the rooftops? – Facets

Rise of the Tweetorial – Precious Bodily Fluids

Social Medicine: Twitter in Healthcare – Journal of Clinical Medicine

University of Twitter? Scientists give impromptu lecture critiquing nutrition research – CBC

Twitter-Based Medicine: How Social Media is Changing the Public’s View of Medicine – The Health Care Blog

What’s your doctor reading? How social media is disrupting medical education – National Post

Commentary from the author on Twitter (thread – click for more)

We wanted to⬆️engagement with @JHepatology research
🤔Hypothesis: people are ⬆️ likely to connect with the people behind the research than the research itself
🧐Plan: Randomize papers to personal story tweets or graphical abstracts
🧐Primary Outcome: paper downloads#livertwitter pic.twitter.com/rxvbGrANRp

— Elliot Tapper (@ebtapper) June 1, 2021

Carbon footprint of general, regional, and combined anesthesia for total knee replacements.

21 Nov, 2021 | 22:50h | UTC

Carbon Footprint of General, Regional, and Combined Anesthesia for Total Knee Replacements – Anesthesia

Global Consensus Statement: Principles of environmentally-sustainable anesthesia.

Environmental and Occupational Considerations of Anesthesia: A Narrative Review and Update.

Working toward the triple bottom line in surgery to limit the impact of surgery on the environment

Effects Of Surgery On A Warming Planet: Can Anesthesia Go Green? – NPR

Anaesthetic gases, climate change, and sustainable practice – The Lancet Planetary Health

Greenhouse gases: the choice of volatile anesthetic does matter – Canadian Journal of Anesthesiology

People, planet and profits: the case for greening operating rooms – Canadian Medical Association Journal

Clinical Guideline Highlights for the Hospitalist: Management of Upper Gastrointestinal and Ulcer Bleeding.

21 Nov, 2021 | 22:44h | UTC

Clinical Guideline Highlights for the Hospitalist: Management of Upper Gastrointestinal and Ulcer Bleeding – Journal of Hospital Medicine (free for a limited period)

Original Guideline: ACG Clinical Guideline: Upper Gastrointestinal and Ulcer Bleeding – RBC transfusion at a threshold of 7 g/dL; Erythromycin infusion is suggested before endoscopy; and endoscopy is suggested within 24 hours after presentation.

M-A: Techniques and technologies to improve peripheral intravenous catheter outcomes in pediatric patients.

21 Nov, 2021 | 22:46h | UTC

Techniques and Technologies to Improve Peripheral Intravenous Catheter Outcomes in Pediatric Patients: Systematic Review and Meta-Analysis – Journal of Hospital Medicine (free for a limited period)

Systematic Review | Integrated and comprehensive pain management programs: effectiveness and harms.

21 Nov, 2021 | 22:43h | UTC

Integrated and Comprehensive Pain Management Programs: Effectiveness and Harms – Agency for Healthcare Research and Quality

Systematic Review | Prehabilitation and rehabilitation for major joint replacement.

21 Nov, 2021 | 22:41h | UTC

Prehabilitation and Rehabilitation for Major Joint Replacement – Agency for Healthcare Research and Quality

RCT: Tofacitinib (oral drug) is an effective treatment in patients with polyarticular course juvenile idiopathic arthritis.

21 Nov, 2021 | 22:38h | UTC

Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial – The Lancet (link to abstract – $ for full-text)

Commentary on Twitter

NEW in @TheLancet — Tofacitinib in juvenile idiopathic #arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial

Flare rate by week 44 was significantly lower with tofacitinib (29%) than with placebo (53%) https://t.co/28JRrbPf8e #JIA pic.twitter.com/JzxHLNmgym

— The Lancet Rheumatology (@TheLancetRheum) November 10, 2021

Revisiting COVID-19 policies: 10 evidence-based recommendations for where to go from here.

19 Nov, 2021 | 10:59h | UTC

Revisiting COVID-19 policies: 10 evidence-based recommendations for where to go from here – BMC Public Health

RECOVERY Trial: Aspirin as an add-on therapy did not reduce mortality in patients hospitalized with COVID-19.

19 Nov, 2021 | 11:01h | UTC

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – The Lancet

Invited Commentary: Studying the coagulopathy of COVID-19 – The Lancet

Commentary from the author on Twitter (thread – click for more)

RECOVERY Publication: ASPIRIN
(a widely used anti-platelet treatment in other settings)

14 892 patients hospitalised with COVID-19.

No impact on mortality.
Small improvement in hospital stay.
No impact on need for mechanical ventilation
6 more bleeds. 6 fewer thromboses (clots) pic.twitter.com/LxDzudss9F

— Martin Landray (@MartinLandray) November 18, 2021

Global tuberculosis progress reversed by COVID-19 pandemic.

19 Nov, 2021 | 10:51h | UTC

Global tuberculosis progress reversed by COVID-19 pandemic – The Lancet Respiratory Diseases

WHO Report: Tuberculosis deaths rise for the first time in more than a decade due to the COVID-19 pandemic.

How COVID is derailing the fight against HIV, TB and malaria.

How COVID hurt the fight against other dangerous diseases

World TB Day | Report: COVID-19 Eliminates Twelve Years of Progress Against Tuberculosis

WHO: Benefits of continuing to provide life-saving HIV services outweigh the risk of COVID-19 transmission by 100 to 1

Tuberculosis and Covid-19: Fighting a deadly syndemic

Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study

Commentary on Twitter

NEWS—Global #tuberculosis progress reversed by #COVID19 pandemic

"Due to the delayed effects from #COVID19, #tuberculosis deaths are projected to rise again in 2022 while the world readjusts to a new normality and services resume."

Read more here: https://t.co/tWVXswZsvs

— The Lancet Respiratory Medicine (@LancetRespirMed) November 3, 2021

Editorial: COVID-19 vaccines for children – “Although it is true that most children experience asymptomatic or mild disease, some will get quite sick, and a small number will die. It’s why children are vaccinated against influenza, meningitis, chickenpox, and hepatitis”.

19 Nov, 2021 | 10:57h | UTC

COVID-19 vaccines for children – Science

Commentary on Twitter

"Although it is true that most children experience asymptomatic or mild COVID disease, some will get quite sick, and a small number will die.

It’s why children are vaccinated against influenza, meningitis, chickenpox, and hepatitis" @DrPaulOffit et al.https://t.co/mvXHXdiYha

— Madhu Pai, MD, PhD (@paimadhu) November 18, 2021

Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine.

19 Nov, 2021 | 10:47h | UTC

Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine – Nature Communications

Commentary: Long-term effectiveness of Pfizer/BioNTech two-dose regimen mRNA vaccine – News Medical

China’s COVID vaccines have been crucial — now immunity is waning.

[Preprint] Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021 – “Vaccine protection declined by mid-August 2021, decreasing from 91.9% in March to 53.9%”.

Observational study in Qatar showed the effectiveness of Pfizer vaccine against any SARS-CoV-2 infection dropped to 20% in months 5 through 7 after the second dose, but effectiveness against severe Covid-19 remained high.

Cohort study: Pfizer vaccine effectiveness against any infections declined from 88% during the first month after full vaccination to 47% after 5 months. Vaccine effectiveness against hospital admissions remained high; 87% within 1 month, and 88% at 5 months after full vaccination, with no significant waning.

Editorial | Covid-19 vaccination: evidence of waning immunity is overstated.

COVID vaccine immunity is waning — how much does that matter? – “As debates about booster shots heat up, what’s known about the duration of vaccine-based immunity is still evolving”.

COVID vaccine effects wane over time but still prevent death and severe illness.

Perspective | What we actually know about waning immunity.

Another study shows Pfizer mRNA vaccine immunity is reduced over time.

[Press release – not published yet] Study shows vaccine protection wanes over time, but vaccines still offer good protection against severe disease.

Studies: COVID vaccine protection waning against infection but not hospitalization.

Commentary on Twitter

A paper in @NatureComms presents preliminary evidence of Pfizer-BioNTech COVID-19 vaccine waning, with a higher incidence of breakthrough infection in people who received their second dose early in 2021 compared to later in the year. https://t.co/QJ7sPZIDuC pic.twitter.com/Gwkj0ugz57

— Nature Portfolio (@NaturePortfolio) November 18, 2021

Stay Updated in Your Specialty